1. Scrip
  2. >>R&D
  3. >>Clinical Trials

UroGen UGN-102 Impresses On Durability Data

 
• By Jessica Merrill

The company announced strong durability data at 12 months for patients with low-grade intermediate risk non-muscle invasive bladder cancer treated with UGN-102. 

target
UroGen durability data for UGN-102 hit the mark • Source: Shutterstock

UroGen Pharma, Ltd. appears well positioned to execute on its expansion strategy based on positive data from the Phase III ENVISION clinical trial testing a proprietary sustained-release formulation of mitomycin, UGN-102, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The company reported the 12-month duration of response (DOR) data on 13 June, showing an 82.3% 12-month DOR in patients who achieved a complete response (CR) at three months after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

More from R&D

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.